Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation

BJU Int. 2014 Feb;113(2):200-8. doi: 10.1111/bju.12321. Epub 2013 Aug 13.

Abstract

Objective: To compare efficacy between radical prostatectomy (RP), radiotherapy and observation with respect to overall survival (OS) in patients with clinically localized prostate cancer (PCa).

Methods: Using data (1988-2005) from the Surveillance, Epidemiology, and End Results-Medicare linked database, 67 087 men with localized PCa were identified. The prevalence of the initial treatment strategy was quantified according to patients' life expectancy ([LE] <10 vs ≥10 years) at initial diagnosis and according to tumour stage. To reduce the unmeasured bias associated with treatment, we performed an instrumental variable analysis. Stratified (by stage and LE) Cox regression and competing-risks regression analyses were generated for the prediction of OS and cancer-specific mortality, respectively.

Results: Among patients with <10 years of LE, most were treated with radiotherapy (49%) or observation (47%). Among patients with ≥10 years of LE, most received radiotherapy (49%), followed by RP (26%). In men with <10 years of LE, RP and radiotherapy were not different with respect to OS (hazard ratio [HR]: 0.81, 95% confidence interval [CI]: 0.45-1.48, P = 0.499). Conversely, in men with ≥10 years of LE, RP was associated with an improved OS compared with observation (HR: 0.59, 95% CI: 0.49-0.71, P < 0.001) and radiotherapy (HR: 0.66, 95% CI: 0.56-0.79, P < 0.001). Similar results were recorded in competing-risks regression analyses.

Conclusion: In patients with an estimated LE ≥10 years at initial diagnosis, RP was associated with improved survival compared with radiotherapy and observation, regardless of disease stage.

Keywords: observation; prostate cancer; prostatectomy; radiotherapy.

Publication types

  • Comparative Study

MeSH terms

  • Age Factors
  • Aged
  • Biomarkers, Tumor / blood*
  • Humans
  • Male
  • Medicare
  • Neoplasm Staging
  • Outcome Assessment, Health Care
  • Prostate-Specific Antigen / blood*
  • Prostatectomy* / statistics & numerical data
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / radiotherapy*
  • Prostatic Neoplasms / surgery*
  • Radiotherapy / statistics & numerical data
  • Risk Assessment
  • Sentinel Surveillance
  • United States / epidemiology
  • Watchful Waiting* / statistics & numerical data

Substances

  • Biomarkers, Tumor
  • Prostate-Specific Antigen